Dr Reddy's Laboratories' sales may be hit as countries attempt to cut costs

Country's second largest drug maker Dr Reddy's Laboratories today said it may see some pressure on revenues as governments around the globe, including the US and India, attempt to cut healthcare costs.

In to a filing to the US Securities and Exchange Commission, DRL, which is listed on NYSE, said these pressures are particularly strong given the lingering effects of the recent global economic and financial crisis, including the ongoing debt crisis in certain countries in Europe.